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ABSTRACT: 
Background: Gum Arabic (GA) is a water-soluble dietary fiber, indigestible to both humans and 
animals. While GA currently does not have any therapeutic potential, it has nutritional value and 
some effects on metabolism of glucose and lipids. Thus, the aim of this study is to assess the effect 
of GA on serum level of glucose, lipids, and the BMI in type 2 diabetic patients. 
 
Methods: A double-blind randomized placebo-controlled trial took place at Academy Charity 
Teaching Hospital (ACTH) in Sudan between August 2014 to February 2015. The trial was 
conducted in type 2 diabetic patients who were on regular oral hypoglycemic drugs and had 
HbA1C ≥ 6.5%. Patients excluded from the study included those on insulin, any patient with a 
metabolic or gastrointestinal disease, and any patient with history of drug addiction and 
alcoholism. Other patients excluded were patients who had previous allergic reactions to GA in 
addition to patients who were pregnant or planned for conception within 6 months. 120 patients 
were invited to participate in this trial. 100 patients gave consent and were randomized to GA and 
placebo groups. The GA group was given 30 g of Acacia Senegal and the placebo group was given 
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5 g of placebo daily for 3 months. The outcomes assessed were primarily the effect of GA on 
glucose levels in addition to the effects on levels of lipids and BMI in type 2 diabetic patients. 
 
Results: The GA group showed significant reduction in fasting plasma glucose (FPG) and HbA1c 
(P<0.05) within the GA group. Moreover, GA supplementation improved lipid profiles; decreased 
LDL-Cholesterol by 5.95%, total Cholesterol by 8.28% and triglyceride by 10.95% from baseline 
levels. HDL-Cholesterol showed significant increase by 19.89% within GA group (P<0.05), BMI 
was decreased significantly by 2.06% (95% CI: −0.98; −0.16), P<0.05). 
 
Conclusions: Gum Arabic is a dietary supplement for improving nutrition of type 2 diabetic 
patients; it has demonstrated a good effect on improving their poor glycemic control. It has also 
shown improvement in the levels of the lipids and the BMI. Further studies are needed in obese 
and pre-diabetic patients to evaluate GA therapeutic potentials. 
 
Trial registration: PACTR201403000785219.  
 
Keywords: Gum Arabic, Diabetes Mellitus type 2, Lipid profiles, Fasting Plasma Glucose, 
Dietary Fibers, HbA1c 
 
BACKGROUND: 
Diabetes is one of the world’s fastest growing chronic diseases. As the prevalence of diabetes 
continues to rise, it will eventually reach a global rise by 2025.According to the International 
Diabetes Foundation (IDF), there are 415 million people with diabetes in the world. By 2040, the 
number of diabetes will increase to 642 million worldwide. The greatest increase in the incidence 
and prevalence of diabetes is in the African population, which is attributed to the dietary habits 
associated with urbanization and westernization [1, 2]. Diabetes increases the risk of developing 
heart diseases [3]. Therefore, the option to reduce this risk by improving dietary habits intake is 
important, especially through advising diabetic patients to increase their intake of dietary fibers. 
However, the amount of fiber intake remains low, despite its well-documented effects in the 
prevention of type 2 diabetes and its complication [4]. Among these dietary fibers is Gum Arabic 
(GA), which is a water-soluble dietary fiber composed of a mixture of polysaccharides, 
oligosaccharides, and glycoproteins. It is exudates of Acacia senegal trees with remarkable 
properties [5]. Gum Arabic dissolves in water, forming a gel-like fluid with a viscous texture. It 
has the ability to slow the absorption and digestion of carbohydrates by the viscosity effect of 
dietary fibers [6], which may alter colonic microbial fermentation to generate short chain fatty acid 
(SCFA) mainly butyrate [7] and thereby possibly reduce the risk of metabolic syndrome [8]. GA 
improves bowel movements [9] with glycemic control [10, 11], and also improves body weight 
[12]. Therefore, this study was conducted to investigate the beneficial effects of consuming 30 g 
of GA with a normal diet for 3 months among type 2 diabetic patients. 
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SUBJECTS AND METHODS: 
Methods 
This is a double-blind randomized placebo-controlled trial that took place at the Academy Charity 
Teaching Hospital (ACTH) in Sudan, carried outfrom August 2014 to February 2015. This study 
was conducted according to the guidelines by the Declaration of Helsinki and procedures were 
approved by the Research Ethics Committee - Khartoum State Ministry of Health and the 
Institutional Review Board at University of Medical Science and Technology (UMST); SUM 116 
-IRB number: 00008867. The trial is registered under PACTR201403000785219. 
 
Patients 
One hundred patients diagnosed with T2DM were recruited in this study from a diabetes outpatient 
clinic that had their regular medical follow-up at the clinic. 
Patients with the following criteria were included in this study: adult diagnosed with type 2 
diabetes mellitus, their fasting plasma glucose is (FPG) ≥7.0 mmol/L (126 mg/dl), HbA1c ≥ 6.5% 
and on oral hypoglycemic medication. 
The exclusion criteria were as follows: alcoholic patients or drug addicts, patients with a 
history of metabolic or gastrointestinal diseases (chronic degenerative and/or inflammatory 
diseases), Type 1 diabetes mellitus or diabetic patients on insulin treatment, history of GA allergy, 
and pregnancy, in addition to women planning to conceive within the next 6 months.  
 
Study design and enrollment 
Only patients approved to participate in this trial by written informed consent were enrolled. 
Patients were randomized and allocated by generating a series of numbers by independent third-
party not associated with the study. Accordingly, the chief attending doctor and participants were 
blinded.  
 
Intervention 
Sealed boxes were prepared containing a supplement from either the intervention GA or pectin 
(placebo) group. A test group of 46 patients received oral GA of 30 g/day for three months and a 
placebo group of 45 patients who received pectin as a placebo for the same period of time. The 
dose of powder GA was divided in two sachets; each sachet containing 15 grams. The sachets 
content was poured in a glass cup containing 250 ml of water, and then were added quickly with 
mixing and shaking to ensure adequate mixing before intake. Both sachets were consumed early 
morning. The dose of placebo was 5 g of pectin. Eligible patients were enrolled randomly and 
allocated either intervention or placebo. No dietary habit restrictions were instructed during the 
trial. However, the enrolled patients were instructed not to change their lifestyle or physical 
activities during the study, and to continue taking their oral hypoglycemic drugs as prescribed by 
their physician. Gum Arabic was provided in a powder form as a gift by “Dar Savanna Ltd. 
Khartoum, Sudan.” Its quality was consistent with the requirements of the Food and Agriculture 
Organization of the United Nations and British pharmacopoeia [13]. 
Daily consumption records were reported using a self-reporting checklist sheet. After 
randomization, a secondary investigator was responsible for enrollment and blinded randomization 
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of supplements. Only the study statistician and the data monitor had un-blinded data, but none of 
them had any contact with study patients. 
 
Outcome measurements 
The primary outcome of this study was the mean percent change of fasting plasma glucose and 
HbA1c from baseline to the end of 3-months follow-up in the GA group. Secondary outcomes 
were mean percent changes in BMI, waist circumference, total cholesterol, triglycerides, low-
density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL). During the 
pre-intervention period, the patients underwent physical examinations, including waist and hip 
circumference, body weight, and height. Investigations included in laboratory tests. Blood samples 
were obtained by veinpuncture, drained in to cryogenic collection tubes, and centrifuged 
immediately at 2700 rpm for 10 minutes to separate plasma from blood. Biochemical analyses 
were performed using BioSystems S.A. Spain. A Quality System certified according to EN ISO 
13485 and EN ISO 9001 standards to determine lipid profile (total cholesterol, HDL-cholesterol, 
LDL-cholesterol, and triglyceride levels), and plasma from the glycolytic inhibitor tube was used 
for measuring fasting plasma glucose level with an international standard for clinical testing 
laboratories [14, 15].  
       Height and weight were measured before breakfast using a calibrated physician's scale to the 
nearest 0.1 cm and 0.1 kg respectively. BMI was calculated directly as weight divided by height 
squared. Each waist was measured at the umbilical level in the standing position after the end of 
light expiration using a measuring tape. These examinations and laboratory tests were performed 
after an overnight fasting condition (10-12 hours). 
 
Statistics 
Data were collected, with double data entry and cross validation used to ensure the validity and 
quality of data. Intention to treat analysis was performed in which all patients who were enrolled 
and randomly allocated are included in the analysis and were analyzed in the groups to which they 
were randomized. The paired t-test was used for the analysis of pre-and post-intervention data. A 
p-value of less than 0.05 was considered statistically significant. 
 
RESULTS: 
Patient enrollment and intervention 
A total of 120 patients were identified as eligible. However, only 100 patients satisfied the 
inclusion criteria and were approved to be enrolled. Three patients had declined to participate. 
During the intervention, two patients got pregnant and were excluded, three patients were found 
to have violated the instructions, and one patient went into surgical operation due to accidental 
trauma. Consequently, the analysis was conducted for the remaining 91 patients as shown in 
(Figure 1). 
 
Characteristics of patients 
The baseline characteristics (mean ± SD) of the 91 patientswere the following: age; 50±9 years, 
duration of diabetes; 61.8±51.8 months, height; 1.6 (0.09) m, weight; 75±14.8 kg and BMI; 
28.8±6.05. During the first two weeks of the intervention and follow-up periods, minor adverse 
reactions were detected in patients enrolled (Table 4). 
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Figure 1: Flow diagram of T2DM patients 
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Characteristics and specifications of Gum Arabic 
 
Table 1: Powdered exudates of Acacia Senegal (Gum Arabic E-414) General specifications 
 
Physical Specification  
Form Powder 
Color Off White 
Smell & Odor None 
Taste Characteristic taste 
Viscosity of 20% Solution 70 - 110 cp 
PH of 20% Solution 4.1-4.8 
Speck Test Per standard 
Moisture <13% 
Total Ash <4% 
Acid Insoluble Residue <1.0% 
Identification Positive 
Starch or Dextrin Negative 
Tannin Bearing Gums Negative 
Heavy Metals   
Arsenic 
Lead 
 
<1.0 mg/kg 
<2.0 mg/kg 
Cadmium <1.0 mg/kg 
Mercury 0.05 mg/kg 
Antimony <1.0 mg/kg 
Tin <40 mg/kg 
Copper <20 mg/kg 
Total Dietary Fibre (As is) >85% 
Total Dietary Fibre (Dry Weight) >90% 
Microbiological specifications  
Total Plate Count cfu/g ≤5 x 105 
Salmonella Abs/Prs in 25g Absent 
Total E. Coli Count Abs/Prs Absent 
Total Yeast & Mold Count cfu/g ≤5 x 104 
Enterobacteriaceae PN/g ≤5 x 103 
Nutritional Information (approximate values per 100 
g) 
Energy 200 Kcal 
Protein 1.9 g 
Available Carbohydrates <0.1 g 
Fat 0.1 g 
Soluble Dietary Fibre 85.5 g 
Soluble Dietary Fibre (Dry Basis) 94 g 
Cholesterol <1 mg 
Sodium 14 mg 
Minerals:  
Calcium 1074 mg 
Potassium 914 mg 
Magnesium 390 mg 
Iron 1.0 mg 
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Table 2: Baseline characteristics of participants in Gum Arabic and Placebo intervention groups 
(n=91). 
 
 
aMean ± SD,bnumber (percentage) 
Variables 
Placebo  
(n=45) 
Gum Arabic 
 (n=46) 
  
 SEM  SEM P 
value 
95% C.I of 
differences 
L             U 
Age (Years) a 50.22±9.29 1.39 49.96±8.73 1.29 0.89 -4.02 3.49 
Male b 6(13.3%)  12(26.1%)  0.19   
Female b 39(86.7%)  34(73.9%)    
Duration of DM (months) a 59.53±48.09 7.17 64.04±55.43 8.17 0.68 -17.13 26.15 
                 ≤60 months b 28 (62.2%)  26 (56.5%)   
0.83 
  
>60 & ≤ 120 b 13 (28.9%)  16 (34.8%)    
>120 months b 4 (8.9)  4 (8.7%)    
Height (cm) a 161.07±8.82 1.31 162.26±9.01 1.33 0.52 -2.52 4.91 
Weight (kg) a 77.07±13.84 2.06 72.86±15.72 2.32 0.18 -10.38 1.96 
BMI (Kg/m2) a 29.96±6.54 0.97 27.66±5.37 0.79 0.07 -4.79 0.19 
               Healthy weight b 10(22.2%)  17(37%)   
 
0.55 
  
              Overweight b 18(40%)  17(37%)    
              Obesity class I b 11(24.4%)  9(19.6%)    
              Obesity class II b 2(4.4%)  1(2.2%)    
              Obesity class III b 4(8.9%)  2(4.3%)    
Waist circumferences (cm) 94.76±14.9 2.22 98.65±12.41 1.83 0.18 -1.81 9.60 
   More than 102 cm (male) b 2(4.4%)  5(10.9%)   
0.33 
  
   Less than 102 cm (male) b 4(8.9%)  7(15.2%)    
   More than 88 cm (female) b 27(60%)  27(58.7%)    
    Less than 88 (female) b 12(26.7%)  7(15.2%)    
HbA1C(%)a 9.59±2.61 0.39 9.23±2.10 0.31 0.71 -1.17 0.80 
Glucose-lowering medication  
         Metformin only b 19(42.2%)  18(39.1%)  0.83   
         Combination therapy b 26(57.8%)  28(60.9%)    
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Table 3: Effect of Gum Arabic and Placebo on glycemic indicators, serum lipid profiles and 
BMI pre and post three months intervention (n=91) 
 
		 Gum	Arabic	(n=46)	 Placebo	(n=45)	
Mean	 SD	 Mean	Differences	
95%	CI	of	the	
Difference	
P	value	 Mean	 SD	 Mean	Differences	
95%	CI	of	the	
Difference	
P	value	
Lower	 Upper	 Lower	 Upper	
BMI	(Kg/m2)	
Pre	 27.66	 5.37	
-0.57		 -0.98	 -0.16	 0.007	
29.96	 6.54	
0.01	
	
-0.07	
	
0.08	
	
	
0.881	
	Post	 27.09	 5.49	 29.96	 6.49	
Waist	
circumference	
(cm)	
Pre	 98.65	 12.41	
-1.30	 -2.97	 0.36	 0.121	
94.76	 14.9	
1.38	
	
-0.56	
	
3.32	
	
	
0.159	
	Post	 97.35	 11.98	 96.13	 15.18	
Fasting	
plasma	
glucose	
(mg/dl)	
Pre	 197.43	 62.09	
-51.83	 -72.02	 -31.63	 0.000	
166.82	 35.88	
0.18	
	
-8.42	
	
8.78	
	
	
0.967	
	Post	 145.61	 38.82	 167	 35.78	
Triglycerides	
(mg/dl)	
Pre	 136.15	 55.74	
-14.93	 -30.58	 0.71	 0.061	
97.62	 47.94	
0.07	
	
-2.55	
	
2.69	
	
	
0.958	
	Post	 121.22	 52.1	 97.69	 46.54	
Total	
Cholesterol	
(mg/dl)	
Pre	 172.7	 41.8	
-14.3	 -2.29	 -26.36	 0.021	
153.47	 40.57	
7.5	 15.06	 -0.04	 0.051	
Post	 158.4	 32.4	 160.98	 40.01	
LDL-
cholesterol	
(mg/dl)	
Pre	 103.1	 40.7	
-19.8	 5.31	 34.23	 0.027	
89.7	 38.4	
8.2	
	
-15.49	
	
0.921	
	
	
0.335	
	Post	 83.3	 43.8	 97.9	 41.9	
HDL-
cholesterol	
(mg/dl)	
Pre	 42.43	 15.16	
8.43	 2.01	 14.86	 0.011	
44.29	 15.22	
-0.71	
	
-2.87	
	
1.45	
	
	
0.511	
	Post	 50.87	 23.48	 43.58	 15.1	
HbA1C(%)	
Pre	
9.23	 2.10	 0.82	 0.29	 1.33	 0.001	
9.59 2.61 
0.18	 -0.24	 0.59	 0.395	
Post	 8.42	 1.73	 9.42 2.63 
 
Effects of GA on metabolic elements 
There was a statistically significant reduction of BMI by 2.1% in the GA group patient after the 
intervention (27.09±5.49 vs. 27.66±5.37 pre-intervention, p<0.05), while no significant change 
was observed in the placebo group (Table 3). Statistically, there was no significant change of waist 
circumference in neither the GA nor the control groups. Regarding the metabolic parameters, 
fasting plasma glucose was significantly reduced by 26.24% in the GA group (145.61±38.82 vs. 
197.43±62.09 pre-intervention, p<0.05), HbA1C decreased by 8.8 % in GA group (8.42±1.73 vs. 
9.23±2.10 pre-intervention, p<0.05) (Table 3). A significant change was observed in LDL-
cholesterol by 19.2 %, and there was a borderline reduction in the level of Triglyceride within GA 
group by 10.95%. However, there was obvious significant increase in the HDL serum level 
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(50.87±23.48 vs. 42.43±15.16 pre-intervention, p<0.05). The serum Total-cholesterol was 
significantly reduced by 8.28% within GA group (Table 3). There were no significant changes in 
all of these parameters in the placebo group except a significant border line increase of total 
cholesterol level. 
 
GA tolerance and side effects 
Patients developed minor side effects during the first week of the intervention and follow-up 
period. Mainly they complained of viscous sensation, diarrhea, nausea, and abdominal bloating. 
However, these symptoms subsided within the second week of intake, with only the discomfort of 
viscous sensation continuing through the interventional study, even though patients were on 
regular consumption of Gum.  
 
Table 4: Side effects of GA among GA group 
Complain Yes 
Total No. (%) 
NO 
pTotal No. (%) 
 
Total 
Abdominal Bloating  6 (13) 40 (87) 46 
Diarrhea  11 (24) 35 (76) 46 
Discomfort with viscous sensation  32 (70) 14 (30) 46 
Nausea  8 (17) 38 (83) 46 
 
DISCUSSION: 
This is the first clinical trial to emphasize the nutritional hypoglycemic and hypolipidemic effect 
of GA on type 2 diabetic patients. In our study, a dose of 30 g/day significantly reduced FPG and 
HbA1c (p<0.05), while a previously suggested mechanism in animal studies proposed that the GA 
decrease expression of intestinal Na+ coupled glucose carrier by down regulating sodium glucose 
transporter1 (SGLT1) carrier with delay in intestinal glucose transport in diabetic mice treated 
with GA [16], this delay leading to the slow absorption of macronutrients, which is usually linked 
to changes in gut peptides resulting in the reduction of postprandial glycemia; on the other hand, 
the down regulation of SGLT1 leads to the enhancement of hunger related hormones including 
leptin, cholecystokinin, and glucagon like peptide 1 [17-20]. These hormones decrease hunger by 
improving post meal satiety through many mechanisms. 
      Additionally, because this is a mechanistic study based on the response of FPG and HbA1c to 
30 g in diabetic patients, the effect of high dose of GA on postprandial blood glucose, satiety 
hormones, along with glucose-lowering medication, needs to be investigated. 
We discovered that the intake of GA with daily diet decreased BMI, with no significant effects on 
waist circumference. Our results support previous studies in which GA modifies the body weight 
and decreased body mass index among healthy adult females [12], reduced weight in rats [21], and 
reduced visceral adipose tissues in female mice [22]. 
      In our study, the changes in anthropometric measurements might be attributed to the satiety 
stimulation effect by high fiber intake [23], which is associated with beneficial effects on fat 
metabolism or lowering caloric density of food [24]. 
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 Unfortunately, we did not measure the total caloric intake from carbohydrate, fats, and protein 
for each group. Moreover, GA has an intrinsic glycemic index near to zero and within itself gives 
less energy if large quantities are taken.  
 Animal studies on lipid-lowering effect of GA in the past few years have demonstrated 
conflict results [21, 25-27]. In human results, conflict is mainly related to dose and duration of GA 
consumption [11, 28-32], as the higher dose and prolonged duration can bring a significant 
improvement of the lipid profiles. However, the tolerability and compliance of a high dose along 
with hypoglycemic medication is unclear and need to be investigated further. 
In our study, we found that GA treatment significantly decreased the total cholesterol by 8.3%, 
triglycerides by 10.9%, LDL 19.2%, and significantly increased HDL level by 19.9% among GA 
treated group. 
The mechanism by which GA intake reduces the plasma cholesterol level may be related to 
the hypocholesterolemic effect of dietary fibers, which can be explained by many mechanisms, 
including viscosity effect of dietary fibers [6], increase fecal bile acids, alteration of lipid 
metabolism [32] and increase number of lipoprotein receptors in the liver [33]. 
Although this study demonstrated that the consumption of 30g of GA improves nutrition of 
type 2 diabetic patients by improving FPG, HbA1c, and lipid profiles, there are some important 
limitations. Patients were treated with metformin alone or combination of drugs; these medications 
have different pharmacological effects. Therefore, further studies based on the types of drugs could 
be considered in the future.  
 
CONCLUSIONS 
The 3-month trial confirmed that regular ingestion of 30g/day of Gum Arabic (Acacia Senegal) 
leads to a range of metabolic changes that deserve attention as dietary supplements for improving 
nutritional value of type 2 diabetic patients with inexpensive and safe type of soluble dietary fiber. 
Future studies are needed to consider this approach in obese and pre-diabetic subjects. 
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